territories should be asked about possible Zika computer virus exposure and the current pregnancy, at every prenatal care visit. the current pregnancy and one that occurred the current pregnancy, particularly for ladies with possible Zika computer virus exposure before the current pregnancy. These limitations should be considered when counseling pregnant women about the risks Aspartame and benefits of screening for Zika computer virus infection during pregnancy. This updated guidance emphasizes a shared Rabbit polyclonal to IL22 decision-making model for screening and screening pregnant women, Aspartame one in which patients and companies work together to make decisions about screening and care plans based on patient preferences and ideals, clinical view, and a balanced assessment of risks and expected results. For these recommendations, the definition of possible Zika computer virus exposure has not changed and includes travel to, or residence in an area with risk for mosquito-borne Zika computer virus transmission or sex with a partner who has traveled to or resides in an area with risk for mosquito-borne Zika computer virus transmission. These areas can be found within the CDC Zika Travel Info webpage.* Key recommendations include the following: 1) All pregnant women in the United States and U.S. territories should be asked about possible Zika computer virus exposure and the current pregnancy, at every prenatal care visit. CDC recommends that pregnant women not travel to any area with risk for Zika computer virus transmission. It is also recommended that pregnant women having a sex partner who has traveled to or lives in an area with risk for Zika computer virus transmission use condoms or abstain from sex for the duration of the pregnancy. 2) Pregnant women with recent possible Zika computer virus exposure and symptoms? of Zika computer virus disease should be tested to diagnose the cause of their symptoms. The updated recommendations include concurrent Zika computer virus nucleic acid test (NAT) and serologic screening as soon as possible through 12 weeks after sign onset. 3) Asymptomatic pregnant women possible Zika computer virus exposure should be offered Zika computer virus NAT testing three times during pregnancy. IgM screening is definitely no longer regularly recommended because IgM can persist for weeks after illness; therefore, IgM results cannot reliably determine whether an infection occurred during the current pregnancy. The optimal timing and rate of recurrence of screening of asymptomatic pregnant women with NAT only is definitely unfamiliar. For pregnant women who have received a analysis of Zika computer virus illness (by either NAT or serology [positive/equivocal Zika computer virus or dengue Aspartame computer virus IgM and Zika computer virus plaque reduction neutralization test (PRNT) 10 and dengue computer virus PRNT 10 results]) any time before or during the current pregnancy, additional Zika computer virus testing is not recommended. For pregnant women without a prior laboratory-confirmed analysis of Zika computer virus, NAT testing should be offered at the initiation of prenatal care, and if Zika computer virus RNA is not detected on medical specimens, two additional checks should be offered during the course of the pregnancy coinciding with prenatal appointments. 4) Asymptomatic pregnant women who have recent? possible Zika computer virus exposure (i.e., through travel or sexual exposure) but possible exposure are not routinely recommended to have Zika computer virus testing. Testing should be considered using a shared patient-provider decision-making model, one in which patients and companies work together to make decisions about screening and care plans based on patient preferences and ideals, clinical view, a balanced assessment of risks and expected results, and the jurisdictions recommendations. Based on the epidemiology of Zika computer virus transmission and additional epidemiologic considerations (e.g., seasonality), jurisdictions might recommend screening of Aspartame asymptomatic pregnant women, either for medical care or as part of Zika computer virus surveillance. With the decrease in the prevalence of Zika computer virus disease, the updated recommendations for the evaluation and screening of pregnant women with recent possible Zika computer virus exposure but possible exposure are now the same for all areas with any risk for Zika computer virus transmission. 5) Pregnant women who have recent possible Zika computer virus exposure and who have a fetus with prenatal ultrasound findings consistent with congenital Zika computer virus syndrome should receive Zika computer virus testing to assist in establishing the etiology of the birth defects. Screening should include both NAT and IgM checks. 6) The comprehensive approach to screening placental and fetal cells has been updated. Screening placental and fetal cells specimens can be performed for diagnostic purposes in certain scenarios (e.g., ladies without a analysis of laboratory-confirmed Zika computer virus infection and who have a fetus or infant with possible Zika virus-associated birth defects**). However, screening of placental cells for Zika computer virus illness is not regularly recommended for asymptomatic pregnant women who have.